Pakistan has moved closer to addressing one of its most neglected public health challenges with renewed efforts to introduce an innovative treatment for Hepatitis Delta Virus (HDV). The development follows the Pakistan-China B2B Health Conference, where discussions between government officials, regulators, researchers, and industry representatives accelerated plans to make a breakthrough therapy available through the Emergency Use Authorization (EUA) mechanism.
The initiative reflects a proactive approach by Federal Minister for National Health Services, Regulations and Coordination, Syed Mustafa Kamal, who has spent the past several months engaging with medical experts and international partners to improve treatment options for patients suffering from this aggressive liver disease. Working alongside renowned hepatologist Prof. Dr. Saeed Hamid and clinical research expert Syed Munawar Ali, the minister, have sought to ensure that Pakistan does not lag behind in accessing cutting-edge therapies. Hepatitis Delta is widely regarded as the most severe form of viral hepatitis because it infects only individuals already carrying the Hepatitis B virus, significantly increasing the risk of liver cirrhosis, liver failure, and cancer. In Pakistan, where hepatitis infections remain a persistent public health concern, experts estimate that more than one million people may be living with suspected HDV, many without diagnosis or appropriate treatment. This alarming figure highlights the urgent need for effective screening, awareness, and access to modern therapies.
The proposed treatment has already attracted international attention after receiving the U.S. Food and Drug Administration’s Breakthrough Therapy Designation, recognizing its potential to address a serious disease with substantial unmet medical need. While the designation is not an approval, it reflects encouraging clinical evidence and allows regulators to expedite the development and review process.
The Pakistan-China B2B Health Conference provided an important platform for translating scientific progress into practical healthcare outcomes. The visit of the chief executive officer of the Chinese biotechnology company developing the therapy underscored growing confidence in Pakistan as both a clinical research destination and an emerging healthcare market. Discussions with the Drug Regulatory Authority of Pakistan (DRAP), led by Chief Executive Officer Dr. Obaid Ullah Malik, focused on facilitating Phase III clinical development while simultaneously advancing the legal and scientific requirements necessary for Emergency Use Authorization.
Equally noteworthy is the collaboration between government institutions and the private sector. LCI Pharma, under the leadership of Chief Executive Officer Atif Siddiqui, is supporting the regulatory process, demonstrating how public-private partnerships can accelerate patient access to life-saving medicines without compromising scientific rigor or safety standards.
Pakistan has already played a role in the international clinical development of this medicine, participating in Phase II trials alongside China, the United States, and Mongolia. The favorable safety profile reported during these studies strengthens confidence in the therapy while showcasing Pakistan’s growing contribution to global medical research.
However, the success of this initiative should not be measured solely by the arrival of a new medicine. The real challenge lies in expanding nationwide screening, improving public awareness, strengthening hepatitis surveillance, and ensuring equitable access to treatment across urban and rural communities. Regulatory approval, while essential, must be accompanied by a comprehensive strategy that includes early diagnosis, physician training, and affordable patient care.